Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00069446
Status:
COMPLETED
Last Update Posted:
2017-05-11
First Post:
2003-09-25
Brief Title:
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor Telbermin for Induction of Healing of Chronic Diabetic Foot Ulcers
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Exploratory Double-Blind Randomized Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor Telbermin for Induction of Healing of Chronic Diabetic Foot Ulcers
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I double blind randomized placebo-controlled study that will enroll approximately 50 adult subjects with Type 1 or Type 2 diabetes mellitus and chronic diabetic foot ulcers The study will be conducted at approximately 12 investigational sites in the United States
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None